India Plans to Introduce First Approved Dengue Vaccine Qdenga in 2027

India to Introduce First Approved Dengue Vaccine Qdenga in 2027

Indian healthcare authorities have announced plans to launch Qdenga, the countrys first approved vaccine for dengue fever, in 2027. The vaccine is the result of a partnership between Takeda Pharmaceutical Company and Dr. Reddy’s Laboratories, a prominent Indian pharmaceutical company.

Dengue fever, transmitted by Aedes mosquitoes, is a significant public health challenge in tropical regions, with millions affected annually. The World Health Organization estimates that approximately 390 million dengue infections occur worldwide each year, with a large percentage being symptomatic.

Qdenga has already received approval in several countries and has shown promise in clinical trials, demonstrating significant efficacy against the dengue virus. The partnership aims to facilitate the vaccines distribution and availability across India, potentially reducing the burden of dengue in one of the countries most affected by the virus.

Dr. Reddy’s Laboratories will be responsible for the marketing and distribution of Qdenga in India, providing an important step in enhancing preventive measures against the potentially severe viral infection. The introduction of Qdenga is anticipated to be a crucial addition to the existing public health measures aimed at combating dengue fever.

This announcement aligns with Indias ongoing efforts to advance its vaccination programs and improve healthcare infrastructure, reflecting a broader commitment to enhancing health security for its population. The full-scale launch is expected to coincide with the upcoming dengue season, thereby maximizing the vaccines impact.